DALLAS, TX — March 22, 2002 — Access Pharmaceuticals, Inc. today announced that Strakan, Ltd., the worldwide licensee of its ResiDerm® technology, has launched Zindaclin on the United Kingdom market.
Also, the process to achieve marketing authorization throughout Europe has been initiated and the first country approvals are expected by the end of 2002.
The United Kingdom Medicines Control Agency approved Zindaclin for once-a-day application for the treatment of acne. Zindaclin is a clindamycin zinc complex in a gel formulation with a prolonged residence in the skin, providing a sustained release effect, which reduces absorption of the drug into the systemic circulation and the associated side effects. Clinical studies confirmed that once-daily dosing was equivalent to the market-leading clindamycin product, which requires twice per day application.
The advantages of Zindaclin over competitive products include: convenient once-daily application (ability to apply last thing in the evening); cosmetically acceptable formulation; stable gel formulation which does not require reconstitution before dispensing; reduced systemic drug exposure.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!